Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
AstraZeneca
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Orca Biosystems, Inc.
National Institutes of Health Clinical Center (CC)
Children's Hospital of Philadelphia
University of Miami
Institute of Hematology & Blood Diseases Hospital, China
Stanford University
MacroGenics
Institute of Hematology and Blood Transfusion, Czech Republic
Wake Forest University Health Sciences
Mayo Clinic
Children's Hospital of Philadelphia
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Thomas Jefferson University
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
University of Wisconsin, Madison
University of Rochester
Mayo Clinic
Mayo Clinic
Affiliated Hospital of Qinghai University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Ossium Health, Inc.
University of Nebraska
Northwestern University
Barbara Ann Karmanos Cancer Institute
University of Rochester
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
University of Florida
Vastra Gotaland Region
Case Comprehensive Cancer Center
Shwachman-Diamond Syndrome Alliance Inc
Imperial College London
Tr1X, Inc.
JaxBio Ltd
NovaOnco Therapeutics Co., Ltd.
Instituto Nacional de Cancer, Brazil